Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12140351 | 1.00 | NR3C1 (0.78) | NR3C1PGR | |
| SCHEMBL14218269 | 0.93 | NR3C1 (0.66) | NR3C1PGR | |
| SCHEMBL1362767 | 0.88 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL1361180 | 0.87 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL1361996 | 0.85 | NR3C1 (0.85) | NR3C1PGR | |
| SCHEMBL1362263 | 0.84 | NR3C1 (0.89) | NR3C1PGR | |
| SCHEMBL1363234 | 0.83 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL1361793 | 0.83 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL1361022 | 0.83 | NR3C1 (1.00) | NR3C1PGR | |
| SCHEMBL1362455 | 0.83 | NR3C1 (1.00) | NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094692-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8067447-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076014-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFRKB, NFKBIA, NFKB1 | NR3C1 11/4885PGR 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.